The effect of dopaminergic medication on speech has rarely been examined in early-stage Parkinson's disease (PD) and the respective literature is inconclusive and limited by inappropriate design with lack of PD control group. The study aims to examine the short-term effect of dopaminergic medication on speech in PD using patients with good motor responsiveness to levodopa challenge compared to a control group of PD patients with poor motor responsiveness. A total of 60 early-stage PD patients were investigated before (OFF) and after (ON) acute levodopa challenge and compared to 30 age-matched healthy controls. PD patients were categorised into two clinical subgroups (PD responders vs. PD nonresponders) according to the comparison of their motor performance based on movement disorder society-unified Parkinson's disease rating scale, part III. Seven distinctive parameters of hypokinetic dysarthria were examined using quantitative acoustic analysis. We observed increased monopitch (p > 0.01), aggravated monoloudness (p > 0.05) and longer duration of stop consonants (p > 0.05) in PD compared to healthy controls, confirming the presence of hypokinetic dysarthria in early PD. No speech alterations from OFF to ON state were revealed in any of the two PD groups and speech dimensions investigated including monopitch, monoloudness, imprecise consonants, harsh voice, slow sequential motion rates, articulation rate, or inappropriate silences, although a subgroup of PD responders manifested obvious improvement in motor function after levodopa intake (p > 0.001). Since the short-term usage of levodopa does not easily affect voice and speech performance in PD, speech assessment may provide a medication state-independent motor biomarker of PD.

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Prague Czech Republic

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of patients with Parkinson’s disease. Behav. Neurol. 1998;11:131–137. PubMed

Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J. Speech Hear Res. 1969;12:246–269. PubMed

Duffy J. R. Motor Speech Disorders: Substrates, Differential Diagnosis and Management 4th edn (Mosby, 2020).

Rusz J, et al. Speech biomarkers in rapid eye movement sleep behavior disorder and Parkinson disease. Ann. Neurol. 2021;90:62–75. PubMed PMC

Cavallieri F, et al. Dopaminergic treatment effects on dysarthric speech: acoustic analysis in a cohort of patients with advanced Parkinson’s disease. Front. Neurol. 2020;11:616062. PubMed PMC

Cushnie-Sparrow D, et al. Voice quality severity and responsiveness to levodopa in Parkinson’s disease. J. Commun. Disord. 2018;76:1–10. PubMed

De Letter M, Santens P, De Bodt M, Boon P, Van Borsel J. Levodopa-induced alterations in speech rate in advanced Parkinson’s disease. Acta Neurol. Belg. 2006;106:19–22. PubMed

De Letter M, et al. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson’s disease. Clin. Neurol. Neurosurg. 2007;109:495–500. PubMed

Fabbri M, et al. Speech and voice response to a levodopa challenge in late-stage Parkinson’s disease. Front. Neurol. 2017;8:432. PubMed PMC

Goberman A, Coelho C, Robb M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J. Commun. Disord. 2002;35:217–239. PubMed

Ho AK, Bradshaw JL, Iansek R. For better or worse: the effect of levodopa on speech in Parkinson’s disease. Mov. Disord. 2008;23:574–580. PubMed

Im H, et al. Effect of levodopa on speech dysfluency in Parkinson’s disease. Mov. Disord. Clin. Pr. 2019;6:150–154. PubMed PMC

Jiang J, Lin E, Wang J, Hanson DG. Glottographic measures before and after levodopa treatment in Parkinson’s disease. Laryngoscope. 1999;109:1287–1294. PubMed

Norel R, et al. Speech-based characterisation of dopamine replacement therapy in people with Parkinson’s disease. NPJ Parkinsons Dis. 2020;6:12. PubMed PMC

Pah ND, Motin MA, Kempster P, Kumar DK. Detecting effect of levodopa in Parkinson’s disease patients using sustained phonemes. IEEE J. Transl. Eng. Health Med. 2021;9:4900409. PubMed PMC

Plowman-Prine EK, et al. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. NeuroRehabilitation. 2009;24:131–144. PubMed

Sanabria J, et al. The effect of levodopa on vocal function in Parkinson’s disease. Clin. Neuropharmacol. 2001;24:99–102. PubMed

Skodda S, Visser W, Schlegel U. Short- and long-term dopaminergic effects on dysarthria in early Parkinson’s disease. J. Neural Transm. 2010;117:197–205. PubMed

Thies T, Mücke D, Dano R, Barbe MT. Levodopa-based changes on vocalic speech movements during prosodic prominence marking. Brain Sci. 2021;11:594. PubMed PMC

Whitfield JA, Reif A, Goberman AM. Voicing contrast of stop consonant production in the speech of individuals with Parkinson disease ON and OFF dopaminergic medication. Clin. Linguist Phon. 2018;32:587–594. PubMed

Nutt JG, Carter JH, Van Houten L, Woodward WR. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann. Neurol. 1997;42:349–355. PubMed

Zappia M, et al. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson’s disease. Ann. Neurol. 1997;42:245–248. PubMed

Rusz J, Cmejla R, Ruzickova H, Klempir J, Majerova V. Evaluation of speech impairment in early stages of Parkinson’s disease: a prospective study with the role of pharmacotherapy. J. Neural Transm. 2012;120:319–329. PubMed

Rusz J, et al. Defining speech subtypes in de-novo Parkinson’s disease: response to long-term levodopa therapy. Neurology. 2021;97:e2124–e2135. PubMed

Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson’s disease result from non-dopaminergic lesions? Neurology. 1987;37:1539–1542. PubMed

Tripoliti E, et al. Predictive factors of speech intelligibility following subthalamic nucleus stimulation in consecutive patients with Parkinson’s disease. Mov. Disord. 2014;29:532–538. PubMed PMC

Pinto S, et al. Functional magnetic resonance imaging exploration of combined hand and speech movements in Parkinson’s disease. Mov. Disord. 2011;26:2212–2219. PubMed PMC

Maillet A, et al. Levodopa effects on hand and speech movements in patients with Parkinson’s disease: a fMRI study. PLos ONE. 2012;7:e46541. PubMed PMC

Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol. 2009;8:1158–1171. PubMed

Louis ED, et al. Progression of parkinsonian signs in Parkinson disease. Arch. Neurol. 1999;56:334–337. PubMed

Skodda S, Gronheit W, Mancinelli N, Schlegel U. Progression of voice and speech impairment in the course of Parkinson’s disease: a longitudinal study. Parkinsons Dis. 2013;2013:389195. PubMed PMC

Tripoliti E, et al. Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology. 2011;76:80–86. PubMed PMC

Rusz J, et al. Smartphone allows capture of speech abnormalities associated with high risk of developing Parkinson’s disease. IEEE Trans. Neural Syst. Rehabil. Eng. 2018;26:1495–1507. PubMed

Contin M, Martinelli P. Pharmacokinetics of levodopa. J. Neurol. 2010;257:S253–S261. PubMed

Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015;30:1591–1601. PubMed

Goetz CG, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 2007;22:41–47. PubMed

Nasreddine ZS, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005;53:695–699. PubMed

Deuschl G, et al. A randomised trial of deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med. 2006;355:896–908. PubMed

Horváth K, et al. Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat. Disord. 2015;2:1421–1426. PubMed

Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson’s disease. Arch. Neurol. 1992;49:1131–1134. PubMed

Rusz J, Tykalova T, Ramig LO, Tripoliti E. Guidelines for speech recording and acoustic analyses in dysarthrias of movement disorders. Mov. Disord. 2021;36:230–238. PubMed

Hlavnicka J. Automated Analysis of Speech Disorders in Neurodegenerative Diseases. Ph.D. thesis, Faculty of Electrical Engineering, Czech Technical Univ. (2018).

Hlavnicka J, et al. Automated analysis of connected speech reveals early biomarkers of Parkinson’s disease in patients with rapid eye movement sleep behaviour disorder. Sci. Rep. 2017;7:12. PubMed PMC

Hlavnicka J, Cmejla R, Klempir J, Ruzicka E, Rusz J. Acoustic tracking of pitch, modal and subharmonic vibrations of vocal folds in Parkinson’s disease and Parkinsonism. IEEE Access. 2019;7:150339–150354.

Acoustic assessment in mandarin-speaking Parkinson's disease patients and disease progression monitoring and brain impairment within the speech subsystem